☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Sotyktu
BMS Presents Three Year Results from the P-III (POETYK PSO) LTE Trial of Sotyktu (deucravacitinib) for Moderate-to-Severe Plaque P...
October 12, 2023
Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu
April 17, 2023
BMS’ Sotyktu (deucravacitinib) Receives EC’s Approval for the Treatment of Plaque Psoriasis
March 29, 2023
Insights+: EMA Marketing Authorization of New Drugs in January 2023
February 23, 2023
BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Sotyktu (deucravacitinib) for Plaque Psoriasis
January 27, 2023
BMS’ Sotyktu (deucravacitinib) Receives the US FDA’s Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis
September 12, 2022
Load more...
Back to Home